E - Glenmark

Active Pharmaceutical Ingredients
Status in FY 2006
Plan going forward…
Revenue decline (12%) driven by:
capacity diversion for captive APIs
across US, India and LRM
decline in prices in some key APIs
Revenue growth in excess of 30%
Complete capacity expansion in
Ankleshwar, start construction in
Aurangabad
discontinuation of Valdecoxib
File 12-14 DMFs per year
Mix of revenues from segments:
India and co-marketing – 48%
Regulated APIs – 22%
Commercial supplies to regulated
markets to increase dramatically with
several ANDA’s/Dossiers filed and
pending from out 3rd party customers
Rest of world – 30%
Commenced commercial supplies of
DMFs during year; several samples,
validation, pivotal batches to global
generic players for their ANDA/Dossier
filings
Develop several APIs annually to
provide cost and timing advantage to
complement our US and EU generic
filings
Continue to be a preferred 3rd party API
supplier to the generic industry
Filed 7 DMFs in the year
Capacity de-bottlenecking initiated for
Ankleshwar, commenced preconstruction
work at new site
Aurangabad